Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 72Genitourinary 8Head & Neck 7Thoracic 5Other solid neoplasm 5Gynecologic 4Tumor-Agnostic 2Sarcoma 2Dermatologic 2CNS 2Endocrine 1Breast 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 10lutetium Lu 177 dotatate 8cabozantinib 4Nivolumab 4Cisplatin 4pembrolizumab 3X-Rays 3Ipilimumab 3Everolimus 3Etoposide 3Carboplatin 3olaparib 2gallium Ga 68 dotatate 2fluorodopa F 18 2fludarabine 2aldesleukin 2Phantoms, Imaging 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 2Cyclophosphamide 2CTLA-4 Antigen 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fluorouracil × Endocrine × 30 days × Clear all
NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Not yet recruiting
240 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡